Date:

March 7, 2005



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:	)
HENNEQUIN et al.	)
Appln. No.: 09/913,020	) Group Art Unit: 1624
Filed: May 6, 2002	) Examiner: Raymond, Richard L.
FOR: QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS	) )

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

## **AMENDMENT AND RESPONSE**

This is in response to the Office Action dated September 7, 2004, the time for responding to which has been extended to and including March 7, 2005, by the petition and authorization for fee payment submitted herewith.

The Examiner's attention is called to the further Information Disclosure Statement and form PTO-1449 submitted herewith, with a copy of the non-US Patent references cited therein.

The Examiner's attention is also drawn to the inquiry at the end of the Remarks with respect to clarification of the status of the certified priority document, which should have been forwarded by the International Bureau. This priority document is listed as having been received in the Notification of Missing Requirements mailed December 6, 2001, but is noted as *not* having been received in the Office Action Summary mailed January 14, 2004.